CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
|
Preferred Stock
Series Seed Preferred Stock
|
Preferred Stock
Series A preferred stock
|
Preferred Stock
Series A-2 Preferred Stock
|
Preferred Stock
Series A-3 Preferred Stock
|
Preferred Stock
Series CF Preferred Stock
|
Preferred Stock
Series B Preferred Stock
|
Preferred Stock
Series A Convertible Preferred Stock
|
Common Stock |
Additional Paid-in Capital |
Accumulated Deficit |
Total |
Beginning balance (in shares) at Dec. 31, 2020 |
20,714,518
|
5,654,072
|
5,932,742
|
9,032,330
|
836,331
|
20,754,717
|
|
6,642
|
|
|
|
Beginning balance at Dec. 31, 2020 |
$ 2,071
|
$ 565
|
$ 593
|
$ 904
|
$ 83
|
$ 2,075
|
|
$ 1
|
$ 27,482,060
|
$ (33,345,997)
|
$ (5,857,645)
|
Stock-based compensation |
|
|
|
|
|
|
|
|
36,976
|
|
36,976
|
Net loss |
|
|
|
|
|
|
|
|
|
(3,023,935)
|
(3,023,935)
|
Ending balance at Mar. 31, 2021 |
$ 2,071
|
$ 565
|
$ 593
|
$ 904
|
$ 83
|
$ 2,075
|
|
$ 1
|
27,519,036
|
(36,369,932)
|
(8,844,604)
|
Ending balance (in shares) at Mar. 31, 2021 |
20,714,518
|
5,654,072
|
5,932,742
|
9,032,330
|
836,331
|
20,754,717
|
|
6,642
|
|
|
|
Beginning balance (in shares) at Dec. 31, 2020 |
20,714,518
|
5,654,072
|
5,932,742
|
9,032,330
|
836,331
|
20,754,717
|
|
6,642
|
|
|
|
Beginning balance at Dec. 31, 2020 |
$ 2,071
|
$ 565
|
$ 593
|
$ 904
|
$ 83
|
$ 2,075
|
|
$ 1
|
27,482,060
|
(33,345,997)
|
(5,857,645)
|
Conversion of preferred stock into common stock |
|
|
|
|
|
|
|
|
|
|
6,293
|
Conversion of debt into common stock |
|
|
|
|
|
|
|
|
|
|
2,680,289
|
Issuance of common stock pursuant to equity line of credit |
|
|
|
|
|
|
|
|
|
|
367,996
|
Net loss |
|
|
|
|
|
|
|
|
|
|
(22,659,480)
|
Ending balance at Sep. 30, 2021 |
|
|
|
|
|
|
|
$ 11
|
57,468,268
|
(56,005,477)
|
1,462,801
|
Ending balance (in shares) at Sep. 30, 2021 |
|
|
|
|
|
|
|
126,275
|
|
|
|
Beginning balance (in shares) at Mar. 31, 2021 |
20,714,518
|
5,654,072
|
5,932,742
|
9,032,330
|
836,331
|
20,754,717
|
|
6,642
|
|
|
|
Beginning balance at Mar. 31, 2021 |
$ 2,071
|
$ 565
|
$ 593
|
$ 904
|
$ 83
|
$ 2,075
|
|
$ 1
|
27,519,036
|
(36,369,932)
|
(8,844,604)
|
Conversion of preferred stock into common stock |
$ (2,071)
|
$ (565)
|
$ (593)
|
$ (904)
|
$ (83)
|
$ (2,075)
|
|
$ 4
|
6,287
|
|
|
Conversion of preferred stock into common stock (shares) |
(20,714,518)
|
(5,654,072)
|
(5,932,742)
|
(9,032,330)
|
(836,331)
|
(20,754,717)
|
|
40,272
|
|
|
|
Issuance of common stock in public offering |
|
|
|
|
|
|
|
$ 2
|
10,000,000
|
|
10,000,002
|
Issuance of common stock in public offering (in shares) |
|
|
|
|
|
|
|
24,096
|
|
|
|
Offering costs |
|
|
|
|
|
|
|
|
(2,116,957)
|
|
(2,116,957)
|
Exercise of over-allotment option, net of offering costs |
|
|
|
|
|
|
|
|
1,364,997
|
|
1,364,997
|
Exercise of over-allotment option, net of offering costs (in shares) |
|
|
|
|
|
|
|
3,614
|
|
|
|
Conversion of debt into common stock |
|
|
|
|
|
|
|
$ 1
|
2,680,288
|
|
2,680,289
|
Conversion of debt into common stock (In shares) |
|
|
|
|
|
|
|
11,352
|
|
|
|
Conversion of related party notes and payables into common stock |
|
|
|
|
|
|
|
|
257,515
|
|
257,515
|
Conversion of related party notes and payables into common stock (in shares) |
|
|
|
|
|
|
|
1,524
|
|
|
|
Common stock and warrants issued in connection with note |
|
|
|
|
|
|
|
|
73,958
|
|
73,958
|
Common stock and warrants issued in connection with note (in shares) |
|
|
|
|
|
|
|
200
|
|
|
|
Common stock issued in connection with business combination |
|
|
|
|
|
|
|
$ 2
|
8,025,540
|
|
8,025,542
|
Common stock issued in connection with business combination (in shares) |
|
|
|
|
|
|
|
21,928
|
|
|
|
Exercise of warrants |
|
|
|
|
|
|
|
|
145,696
|
|
145,696
|
Exercise of warrants (in shares) |
|
|
|
|
|
|
|
319
|
|
|
|
Common stock issued pursuant to consulting agreement |
|
|
|
|
|
|
|
|
183,000
|
|
183,000
|
Common stock issued pursuant to consulting agreement (in shares) |
|
|
|
|
|
|
|
500
|
|
|
|
Stock-based compensation |
|
|
|
|
|
|
|
|
3,801,553
|
|
3,801,553
|
Net loss |
|
|
|
|
|
|
|
|
|
(10,697,498)
|
(10,697,498)
|
Ending balance at Jun. 30, 2021 |
|
|
|
|
|
|
|
$ 10
|
51,940,914
|
(47,067,430)
|
4,873,493
|
Ending balance (in shares) at Jun. 30, 2021 |
|
|
|
|
|
|
|
110,446
|
|
|
|
Issuance of common stock in public offering |
|
|
|
|
|
|
|
|
367,696
|
|
367,696
|
Issuance of common stock in public offering (in shares) |
|
|
|
|
|
|
|
1,264
|
|
|
|
Common stock issued in connection with business combination |
|
|
|
|
|
|
|
$ 1
|
3,403,195
|
|
3,403,196
|
Common stock issued in connection with business combination (in shares) |
|
|
|
|
|
|
|
11,015
|
|
|
|
Exercise of warrants |
|
|
|
|
|
|
|
|
1,622,350
|
|
1,622,350
|
Exercise of warrants (in shares) |
|
|
|
|
|
|
|
3,550
|
|
|
|
Stock-based compensation |
|
|
|
|
|
|
|
|
134,113
|
|
134,113
|
Net loss |
|
|
|
|
|
|
|
|
|
(8,938,047)
|
(8,938,047)
|
Ending balance at Sep. 30, 2021 |
|
|
|
|
|
|
|
$ 11
|
57,468,268
|
(56,005,477)
|
1,462,801
|
Ending balance (in shares) at Sep. 30, 2021 |
|
|
|
|
|
|
|
126,275
|
|
|
|
Beginning balance (in shares) at Dec. 31, 2021 |
|
|
|
|
|
|
|
130,017
|
|
|
|
Beginning balance at Dec. 31, 2021 |
|
|
|
|
|
|
|
$ 13
|
58,614,160
|
(65,703,954)
|
(7,089,781)
|
Stock-based compensation |
|
|
|
|
|
|
|
|
139,093
|
|
139,093
|
Net loss |
|
|
|
|
|
|
|
|
|
(7,832,942)
|
(7,832,942)
|
Conversion of notes into common stock |
|
|
|
|
|
|
|
$ 1
|
1,201,581
|
|
1,201,582
|
Conversion of notes into common stock (in shares) |
|
|
|
|
|
|
|
8,739
|
|
|
|
Ending balance at Mar. 31, 2022 |
|
|
|
|
|
|
|
$ 14
|
59,954,834
|
(73,536,896)
|
(13,582,048)
|
Ending balance (in shares) at Mar. 31, 2022 |
|
|
|
|
|
|
|
138,756
|
|
|
|
Beginning balance (in shares) at Dec. 31, 2021 |
|
|
|
|
|
|
|
130,017
|
|
|
|
Beginning balance at Dec. 31, 2021 |
|
|
|
|
|
|
|
$ 13
|
58,614,160
|
(65,703,954)
|
(7,089,781)
|
Conversion of debt into common stock |
|
|
|
|
|
|
|
|
|
|
1,802,372
|
Net loss |
|
|
|
|
|
|
|
|
|
|
(22,261,338)
|
Ending balance at Sep. 30, 2022 |
|
|
|
|
|
|
$ 1
|
$ 53
|
75,440,940
|
(87,965,292)
|
(12,524,298)
|
Ending balance (in shares) at Sep. 30, 2022 |
|
1
|
|
|
|
|
6,300
|
529,492
|
|
|
|
Beginning balance (in shares) at Mar. 31, 2022 |
|
|
|
|
|
|
|
138,756
|
|
|
|
Beginning balance at Mar. 31, 2022 |
|
|
|
|
|
|
|
$ 14
|
59,954,834
|
(73,536,896)
|
(13,582,048)
|
Issuance of common stock in public offering |
|
|
|
|
|
|
|
$ 37
|
9,347,413
|
|
9,347,450
|
Issuance of common stock in public offering (in shares) |
|
|
|
|
|
|
|
373,898
|
|
|
|
Offering costs |
|
|
|
|
|
|
|
|
(1,930,486)
|
|
(1,930,486)
|
Stock-based compensation |
|
|
|
|
|
|
|
|
119,759
|
|
119,759
|
Net loss |
|
|
|
|
|
|
|
|
|
(9,533,924)
|
(9,533,924)
|
Conversion of notes and derivative liability into common stock |
|
|
|
|
|
|
|
$ 2
|
600,788
|
|
600,790
|
Conversion of notes and derivative liability into common stock (in shares) |
|
|
|
|
|
|
|
16,088
|
|
|
|
Warrants issued in connection with note |
|
|
|
|
|
|
|
|
98,241
|
|
98,241
|
Ending balance at Jun. 30, 2022 |
|
|
|
|
|
|
|
$ 53
|
68,190,549
|
(83,070,820)
|
(14,880,218)
|
Ending balance (in shares) at Jun. 30, 2022 |
|
|
|
|
|
|
|
528,742
|
|
|
|
Common stock issued pursuant to consulting agreement |
|
|
|
|
|
|
|
|
123,000
|
|
123,000
|
Common stock issued pursuant to consulting agreement (in shares) |
|
|
|
|
|
|
|
750
|
|
|
|
Stock-based compensation |
|
|
|
|
|
|
|
|
110,093
|
|
110,093
|
Net loss |
|
|
|
|
|
|
|
|
|
(4,894,472)
|
(4,894,472)
|
Warrants issued in connection with note |
|
|
|
|
|
|
|
|
692,299
|
|
692,299
|
Issuance of Series A preferred stock |
|
|
|
|
|
|
|
|
25,000
|
|
25,000
|
Issuance of Series A preferred stock (in shares) |
|
1
|
|
|
|
|
|
|
|
|
|
Conversion of venture debt into Series A convertible preferred stock |
|
|
|
|
|
|
$ 1
|
|
6,299,999
|
|
6,300,000
|
Conversion of venture debt into Series A convertible preferred stock (in shares) |
|
|
|
|
|
|
6,300
|
|
|
|
|
Ending balance at Sep. 30, 2022 |
|
|
|
|
|
|
$ 1
|
$ 53
|
$ 75,440,940
|
$ (87,965,292)
|
$ (12,524,298)
|
Ending balance (in shares) at Sep. 30, 2022 |
|
1
|
|
|
|
|
6,300
|
529,492
|
|
|
|